NewsRamp is a PR & Newswire Technology platform that enhances press release distribution by adapting content to align with how and where audiences consume information. Recognizing that most internet activity occurs outside of search, NewsRamp improves content discovery by programmatically curating press releases into multiple unique formats—news articles, blog posts, persona-based TLDRs, videos, audio, and Zero-Click content—and distributing this content through a network of news sites, blogs, forums, podcasts, video platforms, newsletters, and social media.
FAQ: Stonegate Capital Partners Initiates Coverage on NeOnc Technologies Holdings, Inc.
TL;DR
Investors can gain an advantage by monitoring NeOnc Technologies' near-term catalysts, including the 2026 NEO100 readout and Quazar Investment funding, for potential stock appreciation.
NeOnc Technologies uses a proprietary intranasal administration strategy to bypass the blood-brain barrier via olfactory and trigeminal pathways for non-invasive CNS therapeutic delivery.
NeOnc's non-invasive CNS therapeutics could improve patient adherence and treatment outcomes for neurological conditions, making tomorrow better for those affected.
NeOnc Technologies is developing NEO100, a patented compound delivered intranasally to reach the brain, with Phase 2a results expected in mid-2026.
Found this article helpful?
Share it with your network and spread the knowledge!
Stonegate Capital Partners has initiated coverage on NeOnc Technologies Holdings, Inc. (NASDAQ: NTHI), a clinical-stage life sciences company developing central nervous system therapeutics.
NeOnc Technologies Holdings, Inc. is a clinical-stage life sciences company developing central nervous system therapeutics designed to overcome the blood-brain barrier, with numerous assets in its pipeline including NEO100.
NEO100 is a patented, pure pharmaceutical compound produced via proprietary synthesis for pharmaceutical-grade purity and reproducibility, and it represents a key asset in NeOnc's pipeline with positive Phase 1/2a results announced in December.
NeOnc's intranasal administration strategy is designed to access the brain via olfactory and trigeminal pathways, offering a non-invasive route intended to improve adherence and enable more direct delivery.
Key near-term catalysts include the NEO100 Phase 2a top-line readout expected in Mid-2026 and the closing and funding of the Quazar Investment expected in the near-term.
Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies, and they have initiated coverage on NeOnc Technologies Holdings, Inc.
The coverage was initiated on January 9th, 2026, with the NEO100 Phase 2a top-line readout expected in Mid-2026 and the Quazar Investment closing expected in the near-term.
To view the full announcement, including downloadable images, bios, and more, click here.
You can contact Stonegate Capital Partners at (214) 987-4121 or via email at info@stonegateinc.com.
Stonegate views NTHI as a differentiated platform supported by favorable tolerability with prolonged dosing and multiple near-term catalysts, which provides professional analysis and visibility for investors considering the company.
Curated from Reportable
